Navigation Links
Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology
Date:4/8/2008

Model Created Using Piecewise Smooth Subdivision Surface Provides Both

Shape and Volumetric Evaluation of Tetralogy of Fallot Patients

SEATTLE, April 8, 2008 /PRNewswire/ -- Three dimensional visualization of the right ventricle provides important shape and volumetric insights that help cardiologists diagnose and treat patients with tetralogy of Fallot (TOF), according to a paper published in the American Journal Cardiology (2008; Vol. 101, Issue 1, 107-113).

TOF is a disease that impacts the heart in multiple ways, such as creating a hole between the ventricles and developing levels of obstruction from the right ventricle to the lungs known as pulmonary stenosis. The three dimensional models created in the study provided volumetric data that was used to determine that patients with TOF had dilated right ventricles compared to individuals with normal function (end-diastolic volume index 216+/- 99 vs 81 +/- 16 ml/mm, p <0.001). The three dimensional models also provided an understanding of changes to the shape of the right ventricle that doctors can use to analyze how the heart adapts to hemodynamic overload.

Entitled "Three-Dimensional Analysis of Right Ventricular Remodeling in Repaired Tetralogy of Fallot," the paper was authored by Dr. Florence H. Sheehan, M.D. The research was a collaboration between investigators at Texas Children's Hospital, Oregon Health & Science University, University of Iowa, and University of Washington in Seattle, Wash. The study used piecewise smooth subdivision reconstruction to create three dimensional models of the hearts of 8 normal subjects and 15 patients with repaired TOF.

"Right ventricle measurement is a critical component in understanding the effectiveness of TOF repair," said Dr. Florence Sheehan, M.D., who is a professor at the University of Washington and chief scientist of VentriPoint Diagnostics Ltd. "We hope to now fully develop the novel diagnostic tools that make the process of accurately obtaining this information easier and much quicker."

Researchers apply the piecewise smooth subdivision surface method by tracing heart borders from many two dimensional images of a heart. VentriPoint Diagnostics is developing a new product, the VentriPoint Diagnostic System (VDS), that enables a similar analysis after a medical professional enters a small number of anatomical points on the heart images. The VDS uses Knowledge Based Reconstruction to automatically compare the points to a database and generate a three dimensional model. This model provides volumetric and anatomical data for the cardiologist.

"The VentriPoint Diagnostic System's ability to rapidly and easily provide right ventricle measurement in multiple disease areas, including tetralogy of Fallot, shows us that this technology will have broad potential once fully developed," said Joseph Ashley, CEO of VentriPoint Diagnostics. "Based on results similar to these from our working prototype, we hope to move into beta testing later this year."

About VentriPoint Diagnostics

VentriPoint creates diagnostic tools to monitor patients with heart disease - the number one cause of death in developed countries. Its lead technology, the VentriPoint Diagnostic System, improves existing medical imaging systems to rapidly and cost effectively obtain measurements that are critical but currently unavailable. Through its technology license and research and development agreements with the University of Washington, VentriPoint is developing this breakthrough diagnostic tool that can provide measurement of a heart's volume and ventricular ejection fraction. The VentriPoint Diagnostic System, together with its associated online service, is being developed for a variety of heart related disease states, including congenital heart disease.

For further information, please contact:

Edward Garth, Chief Financial Officer

VentriPoint Diagnostics Ltd.

Telephone: (206) 283-0221, ext. 402

Facsimile: (206) 283-2309

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

VentriPoint Media Contacts:

Russo Partners LLC

Ian Stone

(619) 814-3510

ian.stone@russopartnersllc.com


'/>"/>
SOURCE VentriPoint Diagnostics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Family of Three Americans Become Pain Free and Improve Their Quality of Life With Stem Cell Treatment in Mexico
2. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
3. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
4. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
5. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
6. Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year
7. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
8. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
9. Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
10. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
11. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
Breaking Medicine News(10 mins):